Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 9:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Subcutaneous injection of saline Clear all
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

NCT04037605
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 4 Interventional Results available

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

NCT01147341
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Placebo
Drug
Lead sponsor
Michael Schiff, MD
Individual
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

NCT03999996
View directory record Official record
Conditions
Dengue Fever
Interventions
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo
Biological
Lead sponsor
Takeda
Industry
Eligibility
13 Years to 63 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
8
States / cities
Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)

NCT01378273
View directory record Official record
Conditions
Extreme Prematurity
Interventions
Epo, Control
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
24 Weeks to 27 Weeks
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Gainesville, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

NCT00353496
View directory record Official record
Conditions
Endocrine Tumors
Interventions
lanreotide (Autogel formulation), Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 27, 2026, 9:47 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

NCT06347003
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
52
States / cities
Garden Grove, California • Lake Forest, California • Montclair, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

NCT00798369
View directory record Official record
Conditions
Acute Gout
Interventions
Canakinumab, Triamcinolone acetonide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Anniston, Alabama • Birmingham, Alabama • Buena Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 2 Interventional

A Randomized, Placebo-Controlled Trial of Stellate Ganglion Block in the Treatment of Post Traumatic Stress Disorder

NCT01629537
View directory record Official record
Conditions
Post Traumatic Stress Disorder (PTSD)
Interventions
Stellate Ganglion Block injection with ropivicane, Placebo Procedure
Procedure
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Rett Syndrome With Recombinant Human IGF-1

NCT01777542
View directory record Official record
Conditions
Rett Syndrome
Interventions
Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2018 · Synced Sep 27, 2026, 9:47 PM EDT
Terminated Not applicable Interventional Results available

Clinical Study to Evaluate the Effect of pH on Pain Upon Local Anesthetic Administration.

NCT01304082
View directory record Official record
Conditions
Local Anesthetics
Interventions
Lidocaine, normal saline, alkalinized lidocaine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
19 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 27, 2026, 9:47 PM EDT
Recruiting Phase 4 Interventional

Frozen Shoulder and Hormone Replacement Therapy

NCT07278323
View directory record Official record
Conditions
Adhesive Capsulitis of the Shoulder, Frozen Shoulder
Interventions
Hormone Replacement Therapy (HRT), Corticosteroid and 1%lidocain, physical therapy
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00262080
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide, Phosphate Buffer Saline (PBS),
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04719832
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
30
States / cities
Encinitas, California • Long Beach, California • Pasadena, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 27, 2026, 9:47 PM EDT
Not listed Phase 3 Interventional

Femoral Nerve Block Compared to Exparel in Total Knee Replacement

NCT02473198
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Exparel, Femoral Nerve Block Bupivacaine, Toradol, Morphine Sulfate
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
18 Years to 73 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SP16 SERPIN-like Peptide Administration in Healthy Individuals

NCT03651089
View directory record Official record
Conditions
Healthy Participants
Interventions
SP16, Placebos
Drug
Lead sponsor
Serpin Pharma, LLC
Other
Eligibility
18 Years to 59 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 4 Interventional Results available

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

NCT05548647
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Treatment, Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 27, 2026, 9:47 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery

NCT07212868
View directory record Official record
Conditions
Non-Diabetic
Interventions
REMD-477 versus Placebo, Exogenous glucagon versus saline infusion
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 27, 2026, 9:47 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

NCT05285137
View directory record Official record
Conditions
Healthy
Interventions
CD388 Injection, Saline placebo
Combination Product · Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 3 Interventional

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

NCT06347133
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
97
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris

NCT01999868
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab, Abatacept, UST Placebo, ABA Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 4 Interventional Results available

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

NCT00993668
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Certolizumab pegol
Other · Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 27, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

NCT03387150
View directory record Official record
Conditions
HIV Infections
Interventions
VRC07-523LS, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 27, 2026, 9:47 PM EDT